The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension

Nicola Orzalesi, Luca Rossetti, Andrea Bottoli, Elena Fumagalli, Paolo Fogagnolo

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Objective: To compare the circadian intraocular pressure (IOP) reductions induced by latanoprost, brimonidine tartrate, and a fixed combination of timolol maleate and dorzolamide hydrochloride in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Methods: In this crossover study, 10 patients with POAG and 10 with OHT were treated with latanoprost once a day, brimonidine twice a day, and a fixed combination of timolol and dorzolamide twice a day for 1 month. Four 24-hour tonometric curves were obtained for each patient. Intraocular pressure (IOP) was measured at 3, 6, and 9 AM, and at noon and at 3, 6, and 9 PM, and at midnight, using a handheld electronic tonometer with the patient in supine and sitting positions and a Goldmann applanation tonometer with the patient sitting at the slitlamp. Main Outcome Measure: Reduction of circadian IOP. Results: All the drugs significantly reduced IOP compared with the baseline at all times, except for brimonidine at midnight, 3 AM, and 6 AM. Latanoprost was more effective than brimonidine in lowering IOP at 3 and 6 AM and at 3 PM (P =.03), and the combination of timolol and dorzolamide was more effective than brimonidine at 3 and 9 AM (P = .04) and at 3 and 6 PM (P = .05) and more effective than latanoprost at 9 AM (P = .05). Conclusion: Latanoprost and the fixed combination of timolol and dorzolamide led to similar circadian reductions in IOP, whereas brimonidine was less effective, particularly during the night.

Original languageEnglish
Pages (from-to)453-457
Number of pages5
JournalArchives of Ophthalmology
Volume121
Issue number4
DOIs
Publication statusPublished - Apr 1 2003

Fingerprint

latanoprost
Ocular Hypertension
Intraocular Pressure
Glaucoma
Supine Position
Posture
Cross-Over Studies
dorzolamide-timolol combination
Brimonidine Tartrate
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. / Orzalesi, Nicola; Rossetti, Luca; Bottoli, Andrea; Fumagalli, Elena; Fogagnolo, Paolo.

In: Archives of Ophthalmology, Vol. 121, No. 4, 01.04.2003, p. 453-457.

Research output: Contribution to journalArticle

@article{d489f0b5f2624a8a9a863ca2918e4169,
title = "The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension",
abstract = "Objective: To compare the circadian intraocular pressure (IOP) reductions induced by latanoprost, brimonidine tartrate, and a fixed combination of timolol maleate and dorzolamide hydrochloride in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Methods: In this crossover study, 10 patients with POAG and 10 with OHT were treated with latanoprost once a day, brimonidine twice a day, and a fixed combination of timolol and dorzolamide twice a day for 1 month. Four 24-hour tonometric curves were obtained for each patient. Intraocular pressure (IOP) was measured at 3, 6, and 9 AM, and at noon and at 3, 6, and 9 PM, and at midnight, using a handheld electronic tonometer with the patient in supine and sitting positions and a Goldmann applanation tonometer with the patient sitting at the slitlamp. Main Outcome Measure: Reduction of circadian IOP. Results: All the drugs significantly reduced IOP compared with the baseline at all times, except for brimonidine at midnight, 3 AM, and 6 AM. Latanoprost was more effective than brimonidine in lowering IOP at 3 and 6 AM and at 3 PM (P =.03), and the combination of timolol and dorzolamide was more effective than brimonidine at 3 and 9 AM (P = .04) and at 3 and 6 PM (P = .05) and more effective than latanoprost at 9 AM (P = .05). Conclusion: Latanoprost and the fixed combination of timolol and dorzolamide led to similar circadian reductions in IOP, whereas brimonidine was less effective, particularly during the night.",
author = "Nicola Orzalesi and Luca Rossetti and Andrea Bottoli and Elena Fumagalli and Paolo Fogagnolo",
year = "2003",
month = "4",
day = "1",
doi = "10.1001/archopht.121.4.453",
language = "English",
volume = "121",
pages = "453--457",
journal = "Archives of Ophthalmology",
issn = "0003-9950",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension

AU - Orzalesi, Nicola

AU - Rossetti, Luca

AU - Bottoli, Andrea

AU - Fumagalli, Elena

AU - Fogagnolo, Paolo

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Objective: To compare the circadian intraocular pressure (IOP) reductions induced by latanoprost, brimonidine tartrate, and a fixed combination of timolol maleate and dorzolamide hydrochloride in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Methods: In this crossover study, 10 patients with POAG and 10 with OHT were treated with latanoprost once a day, brimonidine twice a day, and a fixed combination of timolol and dorzolamide twice a day for 1 month. Four 24-hour tonometric curves were obtained for each patient. Intraocular pressure (IOP) was measured at 3, 6, and 9 AM, and at noon and at 3, 6, and 9 PM, and at midnight, using a handheld electronic tonometer with the patient in supine and sitting positions and a Goldmann applanation tonometer with the patient sitting at the slitlamp. Main Outcome Measure: Reduction of circadian IOP. Results: All the drugs significantly reduced IOP compared with the baseline at all times, except for brimonidine at midnight, 3 AM, and 6 AM. Latanoprost was more effective than brimonidine in lowering IOP at 3 and 6 AM and at 3 PM (P =.03), and the combination of timolol and dorzolamide was more effective than brimonidine at 3 and 9 AM (P = .04) and at 3 and 6 PM (P = .05) and more effective than latanoprost at 9 AM (P = .05). Conclusion: Latanoprost and the fixed combination of timolol and dorzolamide led to similar circadian reductions in IOP, whereas brimonidine was less effective, particularly during the night.

AB - Objective: To compare the circadian intraocular pressure (IOP) reductions induced by latanoprost, brimonidine tartrate, and a fixed combination of timolol maleate and dorzolamide hydrochloride in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Methods: In this crossover study, 10 patients with POAG and 10 with OHT were treated with latanoprost once a day, brimonidine twice a day, and a fixed combination of timolol and dorzolamide twice a day for 1 month. Four 24-hour tonometric curves were obtained for each patient. Intraocular pressure (IOP) was measured at 3, 6, and 9 AM, and at noon and at 3, 6, and 9 PM, and at midnight, using a handheld electronic tonometer with the patient in supine and sitting positions and a Goldmann applanation tonometer with the patient sitting at the slitlamp. Main Outcome Measure: Reduction of circadian IOP. Results: All the drugs significantly reduced IOP compared with the baseline at all times, except for brimonidine at midnight, 3 AM, and 6 AM. Latanoprost was more effective than brimonidine in lowering IOP at 3 and 6 AM and at 3 PM (P =.03), and the combination of timolol and dorzolamide was more effective than brimonidine at 3 and 9 AM (P = .04) and at 3 and 6 PM (P = .05) and more effective than latanoprost at 9 AM (P = .05). Conclusion: Latanoprost and the fixed combination of timolol and dorzolamide led to similar circadian reductions in IOP, whereas brimonidine was less effective, particularly during the night.

UR - http://www.scopus.com/inward/record.url?scp=0037388495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037388495&partnerID=8YFLogxK

U2 - 10.1001/archopht.121.4.453

DO - 10.1001/archopht.121.4.453

M3 - Article

VL - 121

SP - 453

EP - 457

JO - Archives of Ophthalmology

JF - Archives of Ophthalmology

SN - 0003-9950

IS - 4

ER -